Generation and in vitro characterization of engineered cold-adapted influenza A strains with modified NS gene

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: The high variability of influenza strains and the emergence of new variants of viruses lead to the need for constant updating of the composition of influenza vaccines. One of the options for solving this problem is the development of vaccines with enhanced cross-protection against a wide range of influenza strains. Genetically engineered preparations based on live influenza vaccine can be used for targeted stimulation of the cellular immune response. It has been experimentally established that CTL epitopes inserted into the NS gene of the live influenza vaccine strain cause the activation of lymphocytes and the formation of a pool of resident memory T-cells in the lungs of model animals. It is optimal to use experimentally confirmed immunogenic regions for insertion.

AIM: The aim of this study was to rescue a panel of experimental cold-adapted live attenuated influenza vaccine strains with a modified NS gene using A/Leningrad/134/17/57 backbone and recent influenza strains of H1N1, H3N2 and H7N9 subtypes, and evaluate their properties in vitro.

MATERIALS AND METHODS: A cassette encoding immunogenic, conserved among a wide range of influenza strains T-cell epitopes of the influenza virus PB1 protein restricted by common HLA-allotypes was inserted into the gene encoding the NS1 protein. The modified NS gene was cloned into the pCIPolISapIT influenza virus reverse genetics vector. Chimeric influenza viruses were rescued by transfection of Vero cells by electroporation using a standard 8-plasmid system. The growth characteristics of viruses were assessed in developing chicken embryos.

Results: Three strains were successfully obtained based on the live influenza vaccine master donor virus A/Leningrad/ 134/17/57 with a modified NS gene and influenza viruses of the H1N1, H3N2, H7N9 subtypes. Thus, modification of NS gene by insertion of immunogenic PB1 epitopes did not affect the viability and replicative activity of the rescued chimeric live influenza vaccine strains, regardless of the composition of the surface proteins. The strains replicated well at an optimal temperature, had temperature-sensitive phenotype and were able to grow at low temperature.

CONCLUSIONS: The strains will be further studied as candidates for influenza prophylaxis as an experimental universal influenza vaccine.

Full Text

Restricted Access

About the authors

Anna K. Chistyakova

Peter the Great St. Petersburg Polytechnic University

Author for correspondence.
Email: anna.k.chistiakova@gmail.com
ORCID iD: 0000-0001-9541-5636

student

Russian Federation, Saint Petersburg

Polina I. Prokopenko

Institute of Experimental Medicine

Email: pi.prokopenko@gmail.com

Postgraduate student

Russian Federation, Saint Petersburg

Elena V. Krutikova

Institute of Experimental Medicine

Email: krutikova.iem@gmal.com
ORCID iD: 0000-0002-0383-2625
SPIN-code: 6330-6128

Cand. Sci. (Biol.), Researcher

Russian Federation, Saint Petersburg

Ekaterina A. Stepanova

Institute of Experimental Medicine

Email: fedorova.iem@gmail.com
ORCID iD: 0000-0002-8670-8645
SPIN-code: 8010-3047

Cand. Sci. (Biol.), Senior Researcher

Russian Federation, Saint Petersburg

Irina N. Isakova-Sivak

Institute of Experimental Medicine

Email: isakova.sivak@iemspb.ru
ORCID iD: 0000-0002-2801-1508
SPIN-code: 3469-3600

Dr. Sci. (Biol.), Head of Laboratory

Russian Federation, Saint Petersburg

Larisa G. Rudenko

Institute of Experimental Medicine

Email: vaccine@mail.ru
ORCID iD: 0000-0002-0107-9959
SPIN-code: 4181-1372

Dr. Sci. (Med.), Professor, Honored Scientist of the Russian Federation

Russian Federation, Saint Petersburg

References

  1. Isakova-Sivak I, Matyushenko V, Stepanova E, et al. Recombinant live attenuated influenza vaccine viruses carrying conserved T cell epitopes of human adenoviruses induce functional cytotoxic T cell responses and protect mice against both infections. Vaccines (Basel). 2020;8(2):196. doi: 10.3390/vaccines8020196
  2. Kotomina T, Korenkov D, Matyushenko V, et al. Live attenuated influenza vaccine viral vector induces functional cytotoxic T-cell immune response against foreign CD8+ T-cell epitopes inserted into NA and NS1 genes using the 2A self-cleavage site. Hum Vaccin Immunother. 2018;14(12):2964–2970. doi: 10.1080/21645515.2018.1502529
  3. Matyushenko V, Kotomina T, Kudryavtsev I, et al. Conserved T-cell epitopes of respiratory syncytial virus (RSV) delivered by recombinant live attenuated influenza vaccine viruses efficiently induce RSV-specific lung-localized memory T cells and augment influenza-specific resident memory T-cell responses. Antiviral Res. 2020;182:104864. doi: 10.1016/j.antiviral.2020.104864
  4. Isakova-Sivak I, Chen LM, Matsuoka Y, et al. Genetic bases of the temperature-sensitive phenotype of a master donor virus used in live attenuated influenza vaccines: A/Leningrad/134/17/57 (H2N2). Virology. 2011;412(2):297–305. doi: 10.1016/j.virol.2011.01.004
  5. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. American Journal of Epidemiology. 1938;27(3): 493–497. doi: 10.1093/oxfordjournals.aje.a118408
  6. Kiseleva IV, Klimov AI, Grigoryeva EP, et al. Genetic and phenotypic analysis of heterogeneous population of a cold-adapted donor of the A/Leningrad/134/17/57 (H2N2) attenuation and of the donor-based reassortant influenza vaccine strains. Problems of Virology. 2005;50(2):14–18.
  7. Koutsakos M, Illing PT, Nguyen THO, et al. Human CD8+ T cell cross-reactivity across influenza A, B and C viruses. Nat Immunol. 2019;20(5):613–625. doi: 10.1038/s41590-019-0320-6

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2021 Chistyakova A.K., Prokopenko P.I., Krutikova E.V., Stepanova E.A., Isakova-Sivak I.N., Rudenko L.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies